UBS upgrades UK’s Close Brothers on favorable valuation By Investing.com

UBS upgraded Close Brothers (CBRO) to Buy with a 555p target after H1 FY26 adjusted pre-tax profit came in 18% above consensus; stock is down ~25% YTD. Key metrics: NIM 7.1% vs 7.0 consensus, impairments 13% below expectations (cost of risk 0.8%), loans down 2% H/H to £9.2bn. Company guided restructuring spend £10-15m (FY26) and £30-40m (FY27), targeting ~£60m annualised cost savings and >20% headcount reduction (~600 FTE) by end FY27; valuation at 7.3x FY27 EPS and 0.4x TNAV. UBS flagged loan growth must accelerate toward the top of the 5-10% through-cycle target to hit double-digit RoTE, leaving upside contingent on recovery in lending growth and motor provision risk moderation.

Analysis

The market has priced a litigation-and-provision narrative into this stock that creates an asymmetric opportunity: headline fears have compressed multiples, but those same fears raise the bar for positive surprises from improved model assumptions, conservative provisioning outcomes, and visible cost-out delivery. If management can demonstrate a credible run-rate of expense savings and stabilisation in new lending flows over the next 6–12 months, multiple re-rating is likely to outpace fundamental earnings reacceleration because sentiment and TNAV discounts tend to mean-revert faster than credit cycles.

Second-order beneficiaries include mid-tier funders and brokers that will pick up originations if this franchise rightsizes its cost base; counterparties who sell motor-provision analytics and stress-testing models could see higher engagement as the sector re-calibrates. Conversely, firms with heavy exposure to concentrated legacy motor books may face renewed regulatory scrutiny and comparative outflows if redress remains an industry headline — creating a dispersion trade across the UK finance complex.

Key risks are binary and time-staggered: an adverse regulatory decision or a surprise consumer-redress shock can compress equity well before restructuring benefits materialise, while a steady string of positive operational updates should compress implied downside and accelerate capital allocation optionality (dividends/buybacks/asset sales). Watch three cadence items as catalysts over the next 3–12 months — quarterly credit trends, headcount/cost run-rate evidence, and any external validation (ratings, analyst revisions, or activist inquiries) — to shift conviction from tactical to core exposure.

Key Decisions for Investors

• Long CBRO.L (size 2–4% NAV), target +50% over 12 months, stop-loss -25%. Rationale: buy the idiosyncratic recovery vs crowded macro; trim into any short-term pop to lock gains and leave a run-way for restructuring realization.
• Protective collar on CBRO.L for 12 months: buy 25% downside put and fund with selling a 35–45% OTM call. Cost-efficient way to capture upside from de-risking while limiting tail legal/regulatory exposure; expected net debit ~low single-digit percent of position.
• Pair trade (3–9 months): long CBRO.L / short LLOY.L (equal notional). Purpose: isolate idiosyncratic motor-redress and restructuring alpha while hedging UK banking/systemic credit risk. Exit if relative outperformance exceeds 20% or following two consecutive quarters of divergent credit trends.
• Tactical reallocate: trim 10–20% positions in growth/hot-money names (SMCI, APP) and redeploy into CBRO.L on volatility spikes. Risk/reward favors switching from momentum into undervalued, event-driven recovery over a 6–12 month window; monitor flow-driven reversals in tech names and re-deploy if realized volatility compresses.